Matthias Peipp

Kiel, SH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 114 publications

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: May 13, 2026

CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease.

CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease.

Journal: Molecular therapy. Advances

Published: October 13, 2025

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Journal: Blood neoplasia

Published: September 24, 2025

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Journal: HemaSphere

Published: September 09, 2025

Correction: Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer.

Correction: Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer.

Journal: Frontiers in immunology

Published: July 23, 2025

B cell immunity to the Lassa virus glycoprotein is a correlate of vaccination-induced virus control in mice.

B cell immunity to the Lassa virus glycoprotein is a correlate of vaccination-induced virus control in mice.

Journal: Nature communications

Published: May 28, 2025

CD19-ReTARGTPR: A Novel Fusion Protein for Physiological Engagement of Anti-CMV Cytotoxic T Cells Against CD19-Expressing Malignancies.

CD19-ReTARGTPR: A Novel Fusion Protein for Physiological Engagement of Anti-CMV Cytotoxic T Cells Against CD19-Expressing Malignancies.

Journal: Cancers

Published: May 28, 2025

Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer.

Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer.

Journal: Frontiers in immunology

Published: May 14, 2025

IGLV3-21R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.

IGLV3-21R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.

Journal: Haematologica

Published: February 27, 2025

Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager.

Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager.

Journal: Journal of molecular medicine (Berlin, Germany)

Published: February 26, 2025

Novel vanadium-dependent haloperoxidases from macroalgae and their expression in response to biotic and abiotic stressors in Saccharina latissima.

Novel vanadium-dependent haloperoxidases from macroalgae and their expression in response to biotic and abiotic stressors in Saccharina latissima.

Journal: Marine life science & technology

Published: January 21, 2025

Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression.

Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression.

Journal: Frontiers in immunology

Published: August 20, 2024

Showing 1-12 of 114

Last Updated: 09/26/2026